Resveratrol for Women: Sirtuin Hype vs Human Evidence
Researched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Summary
Resveratrol is a polyphenol found in grape skins and Japanese knotweed, marketed as a sirtuin activator and longevity supplement. Human evidence is far less impressive than the mouse and yeast data that made it famous. In women, 75–150 mg/day for 12–24 weeks has shown modest improvements in insulin sensitivity, endothelial function, and (in postmenopausal women specifically) small cognitive and bone-density signals. High doses (>500 mg/day) have caused GI side effects and elevated liver enzymes in some trials. It has weak phytoestrogen activity, which matters if you have hormone-sensitive cancer history. Evidence level: limited to moderate for vascular markers; overstated for lifespan.
Key facts
| Studied dose range | 75–150 mg/day (postmenopausal trials); up to 500 mg with meal for insulin sensitivity |
|---|---|
| Common forms | Trans-resveratrol capsules. Micronized forms (e.g. Resveratrol-MC) have better bioavailability data. |
| Evidence level | Limited |
| Main interaction risks | Weak phytoestrogen; high doses can elevate liver enzymes; interacts with CYP3A4-metabolised drugs. |
What the research shows
RESHAW postmenopausal trial (Evans 2017–2021)
The RESHAW crossover trial (Evans et al., Nutrients 2017; Clin Nutr 2020; J Nutr 2021) enrolled 129 postmenopausal women aged 45–85 and tested 75 mg trans-resveratrol twice daily for 24 months in a 12-month crossover design. It reported improved cerebrovascular responsiveness to cognitive tasks (~17% increase), better verbal memory, improved mood, and modest bone-density preservation at the lumbar spine. This is the longest and largest women-only resveratrol RCT to date, and the most credible women-specific evidence base.
Insulin sensitivity (Timmers 2011, Poulsen 2013)
Timmers et al. (Cell Metab 2011) tested 150 mg/day for 30 days in obese men — HOMA-IR improved and skeletal muscle mitochondrial function increased. Poulsen et al. (Diabetes 2013) then tested 1500 mg/day for 4 weeks and found no benefit — a negative RCT that tempered enthusiasm. The insulin-sensitivity signal appears real at modest doses (150–500 mg) but not consistently reproducible at higher ones.
Endothelial function and BP (Fogacci 2019)
A meta-analysis (Fogacci et al., Crit Rev Food Sci Nutr 2019) of 17 RCTs found resveratrol modestly lowered systolic BP (about 4 mmHg) at ≥300 mg/day and improved flow-mediated dilation. Effect size is comparable to a modest lifestyle intervention.
Cognition and cerebral blood flow (Kennedy 2010, Wong 2016)
Kennedy et al. (Am J Clin Nutr 2010) showed acute single doses of 250–500 mg increased cerebral blood flow measured by near-infrared spectroscopy. Wong et al. (Nutrients 2016) confirmed chronic 14-week dosing at 75 mg twice daily improved cerebrovascular responsiveness in postmenopausal women, mirroring the RESHAW findings.
Estrogenic activity — clinical relevance
Resveratrol is a mixed estrogen-receptor agonist/antagonist in vitro. At supplement doses (75–500 mg), it has not produced measurable estrogenic effects on the endometrium or breast tissue in RCTs. In hormone-receptor-positive breast cancer, however, the mechanism is enough that oncologists typically recommend avoiding it — a precautionary rather than an evidence-based prohibition, but a reasonable one.
High-dose safety (Brown 2010, Almeida 2009)
Doses of 1000–5000 mg/day have produced diarrhea, nausea, and reversible elevations in liver enzymes (Brown et al., Cancer Res 2010; Almeida et al., Mol Nutr Food Res 2009). This is the main safety-driven reason to stay at ≤500 mg/day unless a clinical protocol specifies otherwise.
CYP3A4 inhibition — drug interaction concern
Resveratrol inhibits CYP3A4 in vitro and, at high oral doses, appears to affect the pharmacokinetics of several substrate drugs. Chow et al. (Cancer Prev Res 2010) documented CYP3A4 and CYP2D6 inhibition at 1000 mg/day. At typical supplement doses (75–150 mg), clinically meaningful interactions are uncommon but not zero — particularly relevant for narrow-therapeutic-index drugs like tacrolimus, warfarin, and some anticonvulsants.
Turn this evidence into a personal safety check for Resveratrol.
The interaction checker cross-references Resveratrol against HRT, birth control, thyroid medication, SSRIs, and every other item in your stack — using the same clinical sources cited above.
Check Resveratrol on the interaction checkerInteractions
Interaction risk is what makes women's-health supplements uniquely tricky — HRT, birth control, thyroid medication and SSRIs all share metabolic pathways with common botanicals. Each item below lists the mechanism and what to actually watch for.
- HRTMechanism: Weak additive estrogenic activity; effect at supplement doses is uncertain.Watch for: Discuss with gynecologist; not routinely combined.Check Resveratrol + HRT on the interaction checker
- Tamoxifen / aromatase inhibitorsMechanism: Potential phytoestrogenic interference.Watch for: Avoid without oncology sign-off.Check Resveratrol + Tamoxifen / aromatase inhibitors on the interaction checker
- Blood thinners (warfarin, apixaban)Mechanism: Mild antiplatelet activity in vitro; clinical relevance small at typical doses.Watch for: Monitor if on warfarin; avoid megadoses.Check Resveratrol + Blood thinners (warfarin, apixaban) on the interaction checker
- CYP3A4-metabolised drugs (many statins, some benzodiazepines, tacrolimus, sildenafil)Mechanism: Resveratrol inhibits CYP3A4 in vitro at high doses.Watch for: Discuss with pharmacist if on narrow-therapeutic-index drugs.Check Resveratrol + CYP3A4-metabolised drugs (many statins, some benzodiazepines, tacrolimus, sildenafil) on the interaction checker
- Birth controlMechanism: Weak CYP3A4 inhibition — theoretical, unlikely at typical doses.Watch for: No clinical warnings issued.Check Resveratrol + Birth control on the interaction checker
Who should be cautious
- Breast, uterine, or ovarian cancer history — discuss with oncology before use.
- Pregnancy and breastfeeding — insufficient data; avoid.
- Active liver disease or elevated baseline transaminases.
- Scheduled surgery — stop 2 weeks before due to weak antiplatelet activity.
FAQ
How much resveratrol should a woman take?
The strongest woman-specific evidence uses 75 mg twice daily. Higher doses (>500 mg) don't clearly improve outcomes and increase side-effect risk.
Does resveratrol replace HRT for postmenopause symptoms?
No. Resveratrol's cognitive and bone effects in postmenopausal trials are modest and far smaller than HRT for vasomotor symptoms. It's not a substitute for HRT when HRT is otherwise indicated.
Can I get enough resveratrol from red wine?
No — wine contains milligrams-per-liter amounts, and alcohol offsets any potential benefit. Supplement doses are 50–500× higher.
Does resveratrol interact with birth control?
At typical supplement doses, no clinically documented interaction. Very high doses could theoretically affect CYP3A4-cleared contraceptives; there's no case report evidence.
Is resveratrol safe long-term?
The RESHAW postmenopausal trial ran 24 months at 150 mg/day without safety signals. High doses (1–5 g/day) have caused GI and liver enzyme issues.
Where can I check resveratrol interactions?
Use the DoseRoutine interaction checker at doseroutine.com/interaction-checker to add every longevity supplement plus your HRT, birth control, statin, or thyroid medication in one view.
Taking Resveratrol alongside HRT, birth control, or other supplements?
Get access to all DoseRoutine tools — check your full routine for interactions, log doses and get reminders.
Sign up freeSources
- Evans HM et al. Nutrients 2017 — RESHAW resveratrol postmenopausal 14-week phase.
- Thaung Zaw JJ et al. Clin Nutr 2020 — RESHAW long-term cerebrovascular outcomes.
- Timmers S et al. Cell Metabolism 2011 — Resveratrol metabolic effects in obese men.
- Poulsen MM et al. Diabetes 2013 — High-dose resveratrol negative trial.
- Fogacci F et al. Crit Rev Food Sci Nutr 2019 — Resveratrol and BP meta-analysis.
- Chow HH et al. Cancer Prev Res 2010 — Resveratrol CYP3A4 inhibition.
- NIH Office of Dietary Supplements — Resveratrol fact sheet.
Source: DoseRoutine Library — doseroutine.com/library/womens-health/resveratrol-women